- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00245349
Study to Calculate the Radiation Dosimetry in Subjects With Head and Neck Cancer
Biodistribution and Radiation Dosimetry of F-18 Fluorothymidine (FLT) Imaged With Positron Emission Tomography (PET) in Patients With Head and Neck Cancer: A Radioactive Drug Research Committee (RDRC) Study
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
There are approximately 40,000 new cases of head and neck cancer each year in the United States. Worldwide more than 500,000 individuals will develop head and neck cancer each year, ranking as the sixth most common cancer. These cancers are predominately squamous cell cancers. Approximately two thirds of subjects will present with locally advanced disease with either large disease at the primary site and/or spread to regional lymph node levels.
Despite aggressive treatment, 5-year survival remains poor (overall, approximately 50%). The major site of treatment failure is within the head and neck region, with distant metastases occurring in approximately 25% of subjects and usually after local and/or regional (nodal) failure.
Current treatment options for locally advanced head and neck cancer include combinations of surgery, radiation therapy, and chemotherapy. It is currently difficult to predict which combination will be best suited for any particular individual. Rapid methods of assessing the response of subjects to chemo-radiotherapy would be a useful tool, as it would permit the oncologist to change therapies, either in type or degree, in cases when the subject does not respond to the initial therapy regimen. Current best methods of evaluating tumor response are either serial CT examinations, so that changes in tumor size can be estimated or a fluorodeoxyglucose (FDG) positron emission tomography (PET) study in which changes in the metabolic status of the tumor are evaluated. Unfortunately, the anatomic information afforded by CT examinations often require months after treatment to allow the full effects of therapy to take place. Even after this time, the metabolic activity of any remaining tissue is nearly impossible to assess by CT scan, making it difficult to distinguish between fibrosis and viable tissue. Generally the FDG studies require 3-4 weeks after the end of the therapeutic regime before the relevant information is available, with more reliable information obtained at 3-4 months after treatment.
It is predictable that the most immediate signal of an anti-tumor therapeutic regime that has been successful is that the tumor cells will stop dividing (proliferating) after the therapy is initiated. Therefore, a tracer which is taken up into and retained in cells as a function of their proliferative activity should provide rapid information as to the effectiveness of the treatment. It is the objective of this study to determine the biodistribution and radiation dosimetry of tracer F-18 3'-deoxy-3'-fluorothymidine. This distribution data is essential before an Investigational New Drug (IND) application can be filed with the FDA that would allow the use of this tracer in clinical trials.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa Hospitals and Clinics
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Ability to understand and willingness to sign a written informed consent document.
- Subject must have histologically confirmed stage III, or IV squamous cell carcinoma of the head and neck whose primary origin was from the oral cavity, oropharynx, hypopharynx, or larynx. Carcinoma must be staged using the American Joint Committee on Cancer (AJCC) staging criteria version 6. Adequate tumor must be amenable to biopsy via outpatient methods, therefore the majority of subjects will be those with oropharyngeal lesions.
- Subjects must be scheduled to receive combined chemo-radiotherapy treatment for their standard cancer care. Treatment decisions will be made by the treating otolaryngologist, radiation, and medical oncologists.
- Males or females greater than or equal to 21 years of age. Squamous cell cancer of the head and neck is exceedingly rare in children and not generally applicable to the pediatric population.
- Karnofsky score greater than or equal to 60% at time of screening.
- Life expectancy of greater than 6 months.
Subject must have normal organ and marrow function as defined below:
- leukocytes greater than or equal to 3,000/microL
- absolute neutrophil count greater than or equal to 1,500/microL
- platelets greater than or equal to 100,000/microL
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of normal
- creatinine within normal institutional limits
- BUN within normal institutional limits
- PT and PTT < 2.0 X upper normal limits
- The effects of FLT on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A screening urine hCG will be administered to women of childbearing potential before each FLT scan.
Exclusion Criteria:
- Subjects who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Subject may not be receiving any other investigational agents.
- Subject with a Karnofsky score below 60.
- Pregnant women are excluded from this study. FLT PET has the potential for teratogenic effects. Because there are potentially unknown risks for adverse events in nursing infants secondary to treatment of the mother with FLT, breastfeeding should be discontinued if the mother is imaged with FLT and may not resume for 48 hours after the FLT imaging.
- Subject with an inadequate marrow reserve as determined by history and/or the above tests.
- Subject with a bleeding or clotting dysfunction as determined by medical history and above tests.
- Subjects taking nucleoside analog medications such as those used as antiretroviral agents.
- Inadequate tumor volume to allow for 2 biopsies.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
FLT
Study group receiving FLT for imaging
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Yusuf Menda, MD, University of Iowa, Department of Radiology-Nuclear Medicine
- Hovedetterforsker: Kenneth J Dornfeld, MD, PhD, University of Iowa
- Hovedetterforsker: Timothy Tewson, PhD, University of Iowa, Department of Radiology-Nuclear Medicine
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 200502799
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på F-18 Fluorothymidine
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)FullførtUterine cervikale neoplasmer | Prostatiske neoplasmer | Rektale neoplasmer | Endometriale neoplasmer | Neoplasmer i anusForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtOndartet neoplasmaForente stater
-
Chang Gung Memorial HospitalFullført
-
Chang Gung Memorial HospitalFullførtFrontotemporal demens | Progressiv supranukleær parese | Alzheimers sykdom | Vaskulær kognitiv svikt | Cortical Basal SyndromeTaiwan
-
Siemens Molecular ImagingFudan UniversityFullførtHode- og nakkekreft | Lungekreft | LeverkreftKina
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)TilbaketrukketFluorothymidine F-18 PET ved diagnostisering av pasienter med middels eller høygradig bløtvevssarkomStage III Bløtvevssarkom for voksne | Stage IV Bløtvevssarkom for voksne | Stage II Bløtvevssarkom for voksne | Stage IIA Bløtvevssarkom for voksne | Stage IIB Bløtvevssarkom for voksne | Stage IIC Bløtvevssarkom for voksne
-
Siemens Molecular ImagingFullført
-
ABX advanced biochemical compounds GmbHFullførtProstatakreft | Prostatakreft TilbakevendendeFrankrike
-
Siemens Molecular ImagingFullførtHode- og nakkekreft | LungekreftForente stater
-
Northwell HealthFullførtNevroendokrine svulsterForente stater